CompletedPhase 4ACTRN12624001137583

Effect Of Testosterone Supplements On Anemia And Quality Of Life Amongst Patients On Regular Hemodialysis

Effect Of Testosterone Replacement On Anemia And Quality Of Life Amongst Patients On Maintenance Hemodialysis


Sponsor

Dr Qurat Ul Ain Azam - Pak Emirates Military Hospital

Enrollment

160 participants

Start Date

Jan 1, 2024

Study Type

Interventional

Conditions

Summary

My research focuses on relationship between testosterone replacement and its effects on anaemia and quality of life amongst patients on hemodialysis


Eligibility

Sex: MalesMin Age: 18 YearssMax Age: 80 Yearss

Inclusion Criteria4

  • Patients diagnosed with end-stage renal disease (ESRD) requiring maintenance hemodialysis.
  • Patients with documented anemia, defined as haemoglobin levels < 10 g/dL
  • Patients with stable medical conditions, defined as absence of acute illness or major surgical procedures within the past three months.
  • Patients who have been on a stable hemodialysis regimen for at least three months prior to enrollment.

Exclusion Criteria7

  • Patients with known hypersensitivity or contraindications to testosterone replacement therapy (TRT).
  • Patients with active malignancy, including prostate cancer.
  • Patients with uncontrolled hypertension (systolic blood pressure > 180 mmHg or diastolic blood pressure > 110 mmHg).
  • Patients with severe liver disease (e.g., cirrhosis) or severe hepatic dysfunction (e.g., Child-Pugh class B or C).
  • Patients with severe cardiac disease (e.g., congestive heart failure, recent myocardial infarction) or unstable cardiovascular conditions.
  • Patients with a history of thromboembolic events (e.g., deep vein thrombosis, pulmonary embolism).
  • Patients with significant psychiatric illness or cognitive impairment that may affect their ability to participate in the study or provide informed consent.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

Injection testosterone enanthate 250mg subcut will be given once fortnightly for 6 months it will be administered by a dialysis nurse 30 mins after each dialysis session. Adherence would be ensured a

Injection testosterone enanthate 250mg subcut will be given once fortnightly for 6 months it will be administered by a dialysis nurse 30 mins after each dialysis session. Adherence would be ensured as it will be administered and documented by a dialysis nurse.


Locations(1)

Pakistan

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12624001137583


Related Trials